Drug Profile
Ozanimod - Celgene Corporation
Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIALatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator The Scripps Research Institute
- Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
- Class Amines; Anti-inflammatories; Antivirals; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Multiple sclerosis; Ulcerative colitis
- Phase III Crohn's disease
- Phase II COVID 2019 infections
Most Recent Events
- 29 Feb 2024 Final efficacy and averse events data from the phase III DAYBREAK trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
- 29 Feb 2024 Efficacy data from a phase III SUNBEAM and DAYBREAK trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
- 21 Nov 2023 Celgene completes a phase III trial in Crohn's disease in USA, Turkey, Taiwan, Sweden, South Korea, South Africa, Slovenia, Slovakia, Singapore, Serbia, Saudi Arabia, Russia, Portugal, Netherlands, Mexico, Lithuania, Israel, Hong Kong, Greece, Germany, Canada, Ukraine, Australia, Austria, Brazil, China, Finland, France, Georgia, Colombia and Senegal (PO) (NCT03440385)